文献速递艾滋病与性传播感染

HIV感染者中心性或内脏性肥胖的发病与死亡风险:一项靶向文献综述

Morbidity and Mortality Risk Among People With HIV and Central or Visceral Adiposity: A Targeted Literature Review.
PubMed 文献 · Clin Infect Dis · 2025-01-01

该靶向文献综述检索了Medline/Embase,纳入35项研究(样本量31-1748例HIV感染者),评估内脏脂肪面积和腰围增加与不良健康结局的关系。唯一报告死亡结局的研究显示,内脏脂肪最高者的5年全因死亡风险为2.1倍;内脏脂肪每增加10 cm²,现患心血管疾病风险为1.05倍(95%CI 1.0-1.1)。作者认为腰围可能是内脏肥胖的有用且具成本效益的替代指标。

要点

  • 在唯一报告死亡的研究中,内脏脂肪最高者的5年全因死亡风险为2.1倍。
  • 内脏脂肪每增加10 cm²,现患心血管疾病风险为1.05倍(95%CI 1.0-1.1)。
  • 腰围可能作为内脏肥胖的有用且具成本效益的替代指标。

核心结论

  • 腰围可能是内脏肥胖的有用且具成本效益的替代指标,而内脏肥胖是HIV感染者发病和死亡的重要标志物。

研究设计与样本

  • 靶向文献综述,检索Medline/Embase(2022年6月27日),纳入报告HIV感染者队列的同行评议文章和会议摘要,筛选依据PECOS标准。

主要发现

  • 共纳入35项研究,样本量范围为31至1748例HIV感染者。
  • 25项研究描述了腰围增加与不良健康结局的关系,包括心血管疾病、动脉硬化、高血压、糖尿病、肝脏脂肪与纤维化及认知障碍。
  • 15项研究报告了内脏脂肪增加与不良健康结局的关系,包括全因死亡、心血管疾病、动脉粥样硬化、肝脏脂肪及纤维化。
  • 在唯一报告死亡结局的研究中,内脏脂肪最高者的5年全因死亡风险为2.1倍。
  • 一项研究发现,内脏脂肪每增加10 cm²,现患心血管疾病风险为1.05倍(95%CI:1.0-1.1)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Given the known relationship between human immunodeficiency virus (HIV), antiretroviral therapies, and excess visceral adipose tissue (VAT), this review sought to characterize risk of negative health outcomes associated with excess VAT and increased waist circumference (WC) in people with HIV (PWH). METHODS: Comprehensive targeted literature searches were conducted in Medline/Embase (27 June 2022), identifying peer-reviewed articles and conference abstracts reporting on cohorts of PWH. Screening was guided by PECOS (Population, Exposure, Comparator, Outcomes, Study design) criteria. From the included studies, outcomes of interest including mortality and morbidity risk by VAT area and WC were extracted, overall, and by sex, race/ethnicity, and duration of HIV. Relationships between outcome and exposure variables were summarized. RESULTS: Thirty-five studies were included (sample size range: 31-1748 PWH). Twenty-five studies characterized the relationship between increased WC and negative health outcomes-cardiovascular disease (CVD), arteriosclerosis, hypertension, diabetes, hepatic fat and fibrosis, and cognitive impairment-among PWH. Fifteen studies reported on increased VAT and negative health outcomes: all-cause mortality, CVD, atherosclerosis, hepatic fat, and fibrosis. Importantly, there was a 2.1-times higher odds of 5-year all-cause mortality among PWH with the highest amount of VAT in the only study identified reporting on mortality. Among the studies characterizing the relationship between morbidity and VAT, for example, 1 found that, for each 10-cm2 increase in VAT, the risk of prevalent CVD increased by 1.05 (95% CI: 1.0-1.1) times. CONCLUSIONS: WC may be a useful and cost-effective surrogate for visceral adiposity, which is an important marker of morbidity and mortality among PWH.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bjornson AM, Bedimo RJ, Szabo SM, et al. Morbidity and Mortality Risk Among People With HIV and Central or Visceral Adiposity: A Targeted Literature Review. Clin Infect Dis. 2025. PMID: 39692509. doi:10.1093/cid/ciae543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。